[Ip-health] Nothing Special (301) to report
mirzalas at gmail.com
Sun Apr 17 03:49:35 PDT 2016
the annual IP report is expected soon
The Special 301 Report, an annual feature from the US that evaluates global
intellectual property (IP) protection and enforcement in other countries,
is expected to be out on or before April 30.
The report ranks countries depending on the inadequacy of IP protection and
enforcement into two categories -- priority foreign country (PFC) and
priority watch list (PWL). While a PFC grading obligates the US Trade
Representative (USTR) to initiate unilateral measures like suspension of
trade concessions in case of failure of negotiation, the PWL increases
“bilateral attention concerning the problem areas.”
India is in the PWL category for more than 15 years. And its status will
continue because unlike 2014, there is no demand from the pharmaceutical IP
lobby to categorise India as a PFC.
India’s grade follows complaints made against its patent and drug laws, as
seen in the many submissions to the USTR. One such complaint is that the
Indian Patents Act, especially Section 3 (d), blocks innovation by
preventing patent protection on known chemical substances. In fact, what
this section does is prevent multiple patents on a known substance.
The other grouse involves the grounds for granting compulsory licence (CL)
like the lack of “local working” i.e., it is not produced or made available
locally. Here, the pharma IP lobby ignores the Doha Declaration of the
TRIPS (Trade Related aspects of IP Rights) Agreement on public health,
which clearly states that every WTO Member State has the right to determine
grounds for granting CL.
Another point of contention is that the Drugs and Cosmetics Act does not
police the infringement of patents that takes place when marketing
approvals are given to generic companies on medicines patented by someone
else. In fact, the drug regulator also does not provide data exclusivity
for clinical trial data and approves generic medicines through an
abbreviated procedure, they say.
Contrary to pharma’s complaints, Boeing, in its submission to the USTR,
said that “The Boeing Company conducted a detailed review and determined
that India maintains adequate Intellectual Property Rights legal framework
for the company’s aerospace and defence products… …Boeing continues to have
a positive experience with Indian customers, partners, and suppliers on IPR
protection”. Trade law experts doubt that much will come out of the Special
301 report. According to them, in 1999, the US assured the WTO Dispute
Settlement Panel that it would not initiate any unilateral measures without
the exhaustion of options under the Dispute Settlement Undertaking. This
means the US is supposed to approach the WTO before taking any action
against India on the basis of the Special 301 Report.
But, even as this happens, India’s approach to the US seems to have
changed. And the Government has agreed to bilateral engagement with the US
through a high-level IP working group.
The decision to formulate the National IP policy has only increased
pressure from the US IP maximalist lobby. And according to reports, in the
name of creating an enabling environment for foreign investors to “Make in
India”, officials are said to have given assurances, which undermine public
policy objectives of the Patents Act.
One such assurance said to be given is the non-issuance of CL for
commercial use. And irrespective of the official denial, the rejection of
CL application for Saxagliptin is being seen through this lens.
Policy-makers in India should understand that the Special 301 Report is
merely a pressurising tactic without legal sanctity under international
trade laws. Therefore, the Government should not take any legal or policy
measures to curb the public interest safeguards built into the Indian
Patents Act, which is emerging as a model law for other developing
countries. Because, this will mean a compromise of India’s health security
to please a pharmaceutical IP lobby.
*The writer is with the Third World Network, a non-profit organisation
involved with development issues. Views expressed are personal.*
(This article was published on April 15, 2016)
More information about the Ip-health